Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
Research output: Contribution to journal › Journal article › Research › peer-review
In ROCKET AF, rivaroxaban was non-inferior to adjusted-dose warfarin in preventing stroke or systemic embolism among patients with atrial fibrillation (AF). We aimed to investigate whether the efficacy and safety of rivaroxaban compared with warfarin is consistent among the subgroups of patients with and without previous stroke or transient ischaemic attack (TIA).
| Original language | English |
|---|---|
| Journal | The Lancet Neurology |
| Volume | 11 |
| Issue number | 4 |
| Pages (from-to) | 315-22 |
| Number of pages | 8 |
| ISSN | 1474-4422 |
| DOIs | |
| Publication status | Published - Apr 2012 |
ID: 48592333